Last updated on June 2019

A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma


Brief description of study

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma.

Subjects randomized to Arm 2 (PomDex) may elect, if eligible, to receive VenDex therapy after documented disease progression per International Myeloma Working Group (IMWG) criteria.

Clinical Study Identifier: NCT03539744

Find a site near you

Start Over

Mayo Clinic /ID# 200075

Jacksonville, FL United States
  Connect »

Mayo Clinic - /ID# 201091

Rochester, MN United States
  Connect »

Utah Cancer Specialists /ID# 205788

Salt Lake City, UT United States
  Connect »

CHU Nancy - Brabois /ID# 201076

Vandoeuvre-Lès-Nancy, France
  Connect »

Irccs-Crob /Id# 170955

Rionero in Vulture, Italy
  Connect »

LLC Novaya Clinica /ID# 169689

Pyatigorsk, Russian Federation
  Connect »

Almazov North-West Federal Med /ID# 169681

Sankt-peterburg, Russian Federation
  Connect »

CHU Nancy - Brabois /ID# 201076

Vandoeuvre-Lès-Nancy, France
  Connect »